With aging, phosphorylated-mimetic cMyBP-C mice exhibited better survival, better preservation of systolic and diastolic functions, and unchanging wall thickness compared with control mice.
. Moreover, HF is the leading cause of hospitalization in elderly patients (4) . Despite new treatments, w50% of patients diagnosed with HF will die within 5 years (1) . Therefore, we need to search for novel strategies to treat this deadly disease in our aging population.
Cardiac myosin binding protein-C (cMyBP-C), a heart muscle thick filament protein, can regulate cross-bridge attachment/detachment processes by its phosphorylation status. Once phosphorylated, cMyBP-C accelerates cross-bridge cycling to enhance the ability of the heart to contract and relax (5, 6) .
Hearts from patients with hypertension (7), atrial fibrillation (8), hypertrophic cardiomyopathy (9-11), and HF (9, 11, 12) all exhibit decreased cMyBP-C phosphorylation levels. Moreover, cMyBP-C mutations are a predominant cause of hypertrophic cardiomyopathy that progresses to HF (13) . Thus, there is sufficient evidence to suggest that cMyBP-C phosphorylation mediates normal heart physiology.
We hypothesized that cMyBP-C phosphorylation mitigates aging-related cardiac dysfunction. To test this idea, we used existing mouse models of cMyBP-C phosphorylation mimetic cMyBP-C(t3SD) mutant, cMyBP-C dephosphorylated mimetic cMyBP-C(t3SA) mutant, and cMyBP-C wild-type cMyBP-C(tWT).
These mice were aged to >18 months to mimic a 60-to 70-year-old human. Our studies found that cMyBP-C phosphorylation preserves heart function during aging. generated on an E129X1 (SVE-129) strain (14) . Three cMyBP-C protein kinase-A sites (S273, S282, and S302)
METHODS
were mutated to nonphosphorylatable alanine to mimic phosphorylation deficiency, cMyBP-C(t3SA) (15) , or else substituted to nonphosphorylatable aspartic acid to mimic the negative charge of the phosphorylated residue, cMyBP-C(t3SD) (6) . The cMyBP-C(tWT) control was generated by reintroducing wild-type cMyBP-C into the cMyBP-C (-/-) null background (15) . Because the phosphorylation status of cMyBP-C can change with various conditions, we used cMyBP-C(t3SD), which mimics constitutively phosphorylated cMyBP-C, to test our hypothesis. The 3 models exhibited similar cMyBP-C expression levels: cMyBP-C(tWT): 72%; cMyBP-C(t3SA): 74%; and cMyBP-C(t3SD): 84% (6, 15) .
SURVIVAL. The mice models were aged to >18 months to mimic 60-to 70-year-old human subjects. Both male and female mice were used. Mice euthanized for experiments or for noncardiac reasons (e.g., dermatitis, teeth problems, penile prolapse)
were censored at the date of event. Survival analyses were done on day 600. Mice living beyond 600 days were censored at day 600. Censored mice were not counted as death.
MEASUREMENT OF PHYSIOLOGICAL PARAMETERS.
Blood glucose and systolic blood pressure levels (tail cuff measurements on restrained conscious mice)
were measured in all 3 mice models at 15 to 18 months of age. Mice were euthanized and organs were harvested to measure lung weight/body weight, heart weight/body weight, and heart weight/tibia length ratios as indicators of pulmonary edema and cardiac hypertrophy.
ECHOCARDIOGRAPHY. The Vevo 2100 system (FUJIFILM VisualSonics, Toronto, Ontario, Canada) was used to perform echocardiography on mice 3 to 18 months old by using a previously developed protocol (6). Mice were anesthetized with 0.5% to 2.5% of isoflurane and placed in a warmed echocardiogram Pro-Q Diamond phosphoprotein staining (Thermo Fisher Scientific) was used to estimate the amount of phosphorylated proteins, and Coomassie staining was used to estimate the amount of loaded proteins as previously described (6) . The gel was imaged on a ChemiDoc MP (Bio-Rad, Hercules, California), and band densities were determined by using Image Lab 6.0.1 software.
Rosas et al. software were used to complete statistical analyses.
Kaplan-Meier curves and log-rank tests were used to identify significant differences in survival. Analysis of variance (ANOVA) was used to identify significant differences among 3 groups with a post hoc Tukey All 3 mouse models were aged to 18 to 20 months. Mice that were used for experiments or euthanized for noncardiac causes were censored.
Kaplan-Meier analysis with log-rank testing was then performed to identify differences in survival. Proportional hazard remaining constant was verified by using the Grambsch and Therneau test. cMyBP-C(t3SD) showed the best overall survival.
Rosas et al.
cMyBP-C Phosphorylation Protects Aging Heart Nonfasting blood glucose measurements were similar between mice models age 15 to 18 months ( Figure 2A ).
Tail cuffs were used to measure systolic blood pressure at 15 to 18 months of age. All 3 models exhibited blood pressure levels within normal ranges (mean systolic blood pressure <120 mm Hg) (19) ; however, cMyBP-C(t3SD) showed significantly higher blood pressures than the other 2 groups ( Figure 2B ). cMyBP-C(t3SA) mice exhibited an increased lung/body weight ratio, indicating pulmonary edema ( Figure 2C ).
cMyBP-C(t3SA) mice showed increased heart weight/ 
cMyBP-C Phosphorylation Protects Aging Heart body weight and heart weight/tibia length ratios, suggesting hypertrophy ( Figures 2D and 2E ). Meanwhile, cMyBP-C(t3SD) and cMyBP-C(tWT) mice exhibited similar lung/body, heart/body, and heart/ tibia length ratios. Combination of increased lung/ body weight ratio, heart/body weight ratio, worst cardiac dysfunction according to echocardiography Echocardiography was used to study in vivo cardiac structure and function starting at 3 months until Table 1 ). All mice had similar heart rates ( Figure 3B ). cMyBP-C(t3SA) hearts showed hypertrophy as seen by increased LV posterior wall thickness at diastole starting at 3 months of age. were analyzed with an analysis of variance post hoc Tukey method. Multiple comparisons between all time points within the same strain were not performed.
cMyBP-C Phosphorylation Protects Aging Heart N O V E M B E R 2 0 1 9 : 8 1 7 -3 0 cMyBP-C(tWT) increased LV wall thickness at diastole with aging ( Figure 3D , Supplemental Table 1 ). Meanwhile, cMyBP-C(t3SD) hearts maintained the same LV wall thickness throughout life. cMyBP-C(t3SD) hearts maintained an ejection fraction (EF) >45% ( Figure 3C) and exhibited enhanced contractility with faster tis- ] i decay rate constant (k Ca ) in all mouse models. Repeated measure analysis of variance with intergroup comparison was used to identify significant differences in responses to increasing pacing frequency on intact papillary muscles among the 3 strains. increasing dFR in cMyBP-C(tWT) and cMyBP-C(t3SD)
but not in cMyBP-C(t3SA) (Figures 4A to 4C) . (cTnI), regulated myosin light chain, and titin phosphorylation levels (Supplemental Figure 2) . These findings are similar to those from our previous study (6) . Moreover, we detected no differences in cTnI, regulated myosin light chain, or titin phosphorylation among the 3 strains at old age. However, both cMyBP-C(t3SA) and cMyBP-C(t3SD) strains exhibited different cardiac troponin T and tropomyosin phosphorylation levels than cMyBP-C(tWT) with aging. 
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N O V E M B E R 2 0 1 9 : 8 1 7 -3 0 cMyBP-C Phosphorylation Protects Aging Heart whether differences in tissue fibrosis in the aged mice contributed to the observed differences in diastolic function, systolic function, and hypertrophy. The HOP assay is a method that directly quantifies tissue collagen. We found no differences in the amount of HOP content between the 3 mouse models in the aged hearts or young hearts (Figure 7) . Because there were no significant differences in the amount of HOP between mouse models, we could not attribute heart function and structure differences among the 3 models to differences in fibrosis. However, the cMyBP-C(t3SA) aged hearts exhibited significantly higher HOP content than their younger counterparts.
This finding could explain the more severe decline in systolic and diastolic functions observed in the cMyBP-C(t3SA) model with aging. in a fashion similar to our cMyBP-C models (Supplemental Table 2 ).
DISCUSSION MAINTAINING cMyBP-C PHOSPHORYLATION MITIGATED AGE-RELATED DEVELOPMENT OF CARDIAC DYSFUNCTION.
We aged mouse models of cMyBP-C phosphorylation The cMyBP-C(tWT) age groups consist of: young, 2 to 6 months; middle age, 9 months; and old, 18 to 24 months. cMyBP-C(t3SA) and cMyBP-C(t3SD) strains, which have the known protein kinase-A sites mutated to nonphosphorylatable residues, served as negative controls. cMyBP-C(t3SA) age groups consist of: young, 6 months;
and old, 23 months. cMyBP-C(t3SD) age groups consist of: young, 3 to 4 months; old, 20 and 24 months. showed that acceleration of cross-bridge cycling by phosphorylated cMyBP-C also resulted in enhanced relaxation (6) .
In the present study, cTnI phosphorylation did not differ among the 3 mouse models; therefore, differences in function cannot be attributed to differences in cTnI phosphorylation (Supplemental Figure 2) . Furthermore, similar levels of cTnI phosphorylation suggest that protein kinase-A and protein kinase-C overall activity remained similar among the 3 mouse models. We acknowledge that cardiac troponin T and tropomyosin phosphorylation levels changed in the cMyBP-C(t3SA) and cMyBP-C(t3SD) models with aging; however, we believe that these changes are compensatory mechanisms Figure 3E ) (25) . E/e 0 ratios were higher in the cMyBP-C(t3SA) and cMyBP-C(tWT) models, suggesting compromised diastolic function ( Figure 3F ) (25) .
Also, cMyBP-C(t3SA) and cMyBP-C(tWT) exhibited increased posterior ventricular wall thickness with aging ( Figure 3D) , reminiscent of human LV hypertrophy with HFpEF (26, 27) . Similar to our findings, echocardiographic data from humans showed that age is associated with increased LV mass (increasing wall thickness) and EF abnormalities (28, 29) . Meanwhile, cMyBP-C(t3SD) maintains a constant wall thickness with aging ( Figure 3D ), suggesting that cMyBP-C phosphorylation prevented remodeling.
Better POTENTIAL STUDY LIMITATIONS. The 3 mouse models have incomplete expression of cMyBP-C of 72% to 84% in the myofilaments (6) . However, because cMyBP-C expression levels among the models are similar, the functional differences are most likely caused by the phosphorylation status.
Our study did not address murine cMyBP-C phosphorylation sites outside of S273, S282, and S302 Thus, a follow-on study of mimicing isolated cMyBP-C phosphorylation with cardiac trophic adeno-associated virus expression of cMyBP-C phosphorylation mimetics after aging is needed to better define specificity of the cMyBP-C phosphorylation effect. We also understand that our results need to be confirmed in a large animal model that better resembles humans.
CONCLUSIONS
We aged mouse models to test the hypothesis that 
